Metalloproteinase expression is altered in cardiac and skeletal muscle in cancer cachexia

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 309, Issue 4, 2015, Pages H685-H691

  Devine, Raymond D ^a,b   Bicer, Sabahattin ^b   Reiser, Peter J ^b   Velten, Markus ^c   Wold, Loren E ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Cancer cachexia; Extracellular matrix; Matrix metalloproteinase; Tissue inhibitors of matrix metalloproteinase

Indexed keywords

COLLAGEN; GELATINASE A; GELATINASE B; HYDROXYPROLINE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; RNA; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; MESSENGER RNA;

ADENOCARCINOMA; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BLOOD LEVEL; CACHEXIA; CELL INTERACTION; COLLAGEN METABOLISM; DRUG TARGETING; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; HEART FAILURE; HEART LEFT VENTRICLE; HEART MUSCLE; HEART MUSCLE FIBROSIS; MOUSE; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE; STAINING; ANIMAL; BAGG ALBINO MOUSE; COMPLICATION; DBA MOUSE; EXPERIMENTAL NEOPLASM; GENETICS; METABOLISM;

ANIMALS; CACHEXIA; FEMALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MUSCLE, SKELETAL; MYOCARDIUM; NEOPLASMS, EXPERIMENTAL; RNA, MESSENGER;

EID: 84939457497     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00106.2015     Document Type: Article

References (45)

1. Adams V, Linke A, Wisloff U, Doring C, Erbs S, Krankel N, Witt CC, Labeit S, Muller-Werdan U, Schuler G, Hambrecht R. Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: Effect on myocardial contractility. Cardiovasc Res 73: 120–129, 2007.
2. Ali MA, Fan X, Schulz R. Cardiac sarcomeric proteins: novel intracellular targets of matrix metalloproteinase-2 in heart disease. Trends Cardiovasc Med 21: 112–118, 2011.
3. Argiles JM, Busquets S, Lopez-Soriano FJ. Anti-inflammatory therapies in cancer cachexia. Eur J Pharmacol 668, Suppl 1: S81–S86, 2011.
4. Argiles JM, Busquets S, Lopez-Soriano FJ. The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol 37: 2036–2046, 2005.
5. Aulino P, Berardi E, Cardillo VM, Rizzuto E, Perniconi B, Ramina C, Padula F, Spugnini EP, Baldi A, Faiola F, Adamo S, Coletti D. Molecular, cellular and physiological characterization of the cancer cachexia- inducing C26 colon carcinoma in mouse. BMC Cancer 10: 363, 2010.
6. Bicer S, Reiser PJ. Myosin light chain 1 isoforms in slow fibers from global and orbital layers of canine rectus muscles. Invest Ophthalmol Vis Sci 45: 138–143, 2004.
7. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L, AtheroGene I. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107: 1579–1585, 2003.
8. Blough ER, Rennie ER, Zhang F, Reiser PJ. Enhanced electrophoretic separation and resolution of myosin heavy chains in mammalian and avian skeletal muscles. Anal Biochem 233: 31–35, 1996.
9. Carrasco FH, Montes GS, Krisztan RM, Shigihara KM, Carneiro J, Junqueira LC. Comparative morphologic and histochemical studies on the collagen of vertebrate arteries. Blood Vessels 18: 296–302, 1981.
10. Cohen S, Brault JJ, Gygi SP, Glass DJ, Valenzuela DM, Gartner C, Latres E, Goldberg AL. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol 185: 1083–1095, 2009.
11. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9–34, 2006.
12. Dewald O, Frangogiannis NG, Zoerlein M, Duerr GD, Klemm C, Knuefermann P, Taffet G, Michael LH, Crapo JD, Welz A, Entman ML. Development of murine ischemic cardiomyopathy is associated with a transient inflammatory reaction and depends on reactive oxygen species. Proc Natl Acad Sci USA 100: 2700–2705, 2003.
13. DeWys WD. Nutritional care of the cancer patient. JAMA 244: 374–376, 1980.
14. Fouladiun M, Korner U, Gunnebo L, Sixt-Ammilon P, Bosaeus I, Lundholm K. Daily physical-rest activities in relation to nutritional state, metabolism, and quality of life in cancer patients with progressive cachexia. Clin Cancer Res 13: 6379–6385, 2007.
15. Fukushima K, Nakamura A, Ueda H, Yuasa K, Yoshida K, Takeda S, Ikeda S. Activation and localization of matrix metalloproteinase-2 and -9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ). BMC Musculoskel Disord 8: 54, 2007.
16. Halade GV, Jin YF, Lindsey ML. Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther 139: 32–40, 2013.
17. He WA, Berardi E, Cardillo VM, Acharyya S, Aulino P, Thomas- Ahner J, Wang J, Bloomston M, Muscarella P, Nau P, Shah N, Butchbach ME, Ladner K, Adamo S, Rudnicki MA, Keller C, Coletti D, Montanaro F, Guttridge DC. NF-B-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J Clin Invest 123: 4821–4835, 2013.
18. Hnia K, Hugon G, Rivier F, Masmoudi A, Mercier J, Mornet D. Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophin-deficient Mdx mice. Am J Pathol 170: 633–643, 2007.
19. Kedar V, McDonough H, Arya R, Li HH, Rockman HA, Patterson C. Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc Natl Acad Sci USA 101: 18135–18140, 2004.
20. Khal J, Wyke SM, Russell ST, Hine AV, Tisdale MJ. Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia. Br J Cancer 93: 774–780, 2005.
21. Kherif S, Lafuma C, Dehaupas M, Lachkar S, Fournier JG, Verdiere- Sahuque M, Fardeau M, Alameddine HS. Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx muscles. Dev Biol 205: 158–170, 1999.
22. Kumar A, Bhatnagar S, Kumar A. Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice. Am J Pathol 177: 248–260, 2010.
23. Lazarus DD, Destree AT, Mazzola LM, McCormack TA, Dick LR, Xu B, Huang JQ, Pierce JW, Read MA, Coggins MB, Solomon V, Goldberg AL, Brand SJ, Elliott PJ. A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway. Am J Physiol Endocrinol Metab 277: E332–E341, 1999.
24. Lemaitre V, D’Armiento J. Matrix metalloproteinases in development and disease. Birth Defects Res C Embryo Today 78: 1–10, 2006.
25. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P, Burden SJ, Di Lisi R, Sandri C, Zhao J, Goldberg AL, Schiaffino S, Sandri M. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab 6: 458–471, 2007.
26. Murphy KT, Chee A, Trieu J, Naim T, Lynch GS. Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia. Dis Model Mechan 5: 533–545, 2012.
27. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69: 562–573, 2006.
28. Ohtake Y, Tojo H, Seiki M. Multifunctional roles of MT1-MMP in myofiber formation and morphostatic maintenance of skeletal muscle. J Cell Sci 119: 3822–3832, 2006.
29. Roberts BM, Ahn B, Smuder AJ, Al-Rajhi M, Gill LC, Beharry AW, Powers SK, Fuller DD, Ferreira LF, Judge AR. Diaphragm and ventilatory dysfunction during cancer cachexia. FASEB J 27: 2600–2610, 2013.
30. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117: 399–412, 2004.
31. Shirakabe A, Asai K, Hata N, Yokoyama S, Shinada T, Kobayashi N, Mizuno K. Clinical significance of matrix metalloproteinase (MMP)-2 in patients with acute heart failure. Int Heart J 51: 404–410, 2010.
32. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 64: 9–29, 2014.
33. Springer J, Tschirner A, Haghikia A, von Haehling S, Lal H, Grzesiak A, Kaschina E, Palus S, Potsch M, von Websky K, Hocher B, Latouche C, Jaisser F, Morawietz L, Coats AJ, Beadle J, Argiles JM, Thum T, Foldes G, Doehner W, Hilfiker-Kleiner D, Force T, Anker SD. Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J 35: 932–941, 2014.
34. Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, Narusawa M, Leferovich JM, Sladky JT, Kelly AM. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352: 536–539, 1991.
35. Tian M, Asp ML, Nishijima Y, Belury MA. Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice. Int J Oncol 39: 1321–1326, 2011.
36. Tian M, Nishijima Y, Asp ML, Stout MB, Reiser PJ, Belury MA. Cardiac alterations in cancer-induced cachexia in mice. Int J Oncol 37: 347–353, 2010.
37. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2: 862–871, 2002.
38. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 89: 381–410, 2009.
39. Toth MJ, Miller MS, Callahan DM, Sweeny AP, Nunez I, Grunberg SM, Der-Torossian H, Couch ME, Dittus K. Molecular mechanisms underlying skeletal muscle weakness in human cancer: reduced myosinactin cross-bridge formation and kinetics. J Appl Physiol 114: 858–868, 2013.
40. Trim JE, Samra SK, Arthur MJ, Wright MC, McAulay M, Beri R, Mann DA. Upstream tissue inhibitor of metalloproteinases-1 (TIMP-1) element-1, a novel and essential regulatory DNA motif in the human TIMP-1 gene promoter, directly interacts with a 30-kDa nuclear protein. J Biol Chem 275: 6657–6663, 2000.
41. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827–839, 2003.
42. Wang XS. Pathophysiology of cancer-related fatigue. Clin J Oncol Nurs 12: 11–20, 2008.
43. White JP, Puppa MJ, Sato S, Gao S, Price RL, Baynes JW, Kostek MC, Matesic LE, Carson JA. IL-6 regulation on skeletal muscle mitochondrial remodeling during cancer cachexia in the ApcMin/+ mouse. Skelet Muscle 2: 14, 2012.
44. Xu H, Crawford D, Hutchinson KR, Youtz DJ, Lucchesi PA, Velten M, McCarthy DO, Wold LE. Myocardial dysfunction in an animal model of cancer cachexia. Life Sci 88: 406–410, 2011.
45. Zhang L, Tang H, Kou Y, Li R, Zheng Y, Wang Q, Zhou X, Jin L. MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia. J Cancer Res Clin Oncol 139: 1105–1115, 2013.